BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35780773)

  • 21. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
    Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF
    J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTP4A3 Independently Predicts Metastasis and Survival in Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy.
    Yeh HC; Li CC; Huang CN; Hour TC; Yeh BW; Li WM; Liang PI; Chang LL; Li CF; Wu WJ
    J Urol; 2015 Nov; 194(5):1449-55. PubMed ID: 26070892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
    Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
    Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review.
    van Doeveren T; van de Werken HJG; van Riet J; Aben KKH; van Leeuwen PJ; Zwarthoff EC; Boormans JL
    Urol Oncol; 2020 Jun; 38(6):590-598. PubMed ID: 32057596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
    Fontugne J; Xylinas E; Krucker C; Dixon V; Groeneveld CS; Pinar U; Califano G; Bucau M; Verine J; Desgrandchamps F; Hermieu JF; Radvanyi F; Allory Y; Masson-Lecomte A
    Mod Pathol; 2023 Nov; 36(11):100300. PubMed ID: 37558130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations.
    Williamson SR; Wang M; Montironi R; Eble JN; Lopez-Beltran A; Zhang S; Fan R; Wang L; Osunkoya AO; Koch MO; Cheng L
    Mod Pathol; 2014 Nov; 27(11):1540-8. PubMed ID: 24743222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M; Kim B; Moon KC
    Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?
    Krabbe LM; Bagrodia A; Westerman ME; Gayed BA; Haddad AQ; Sagalowsky AI; Shariat SF; Kapur P; Lotan Y; Margulis V
    World J Urol; 2016 Jan; 34(1):105-12. PubMed ID: 25991599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    Petros FG; Choi W; Qi Y; Moss T; Li R; Su X; Guo CC; Czerniak B; Dinney C; McConkey DJ; Matin SF
    J Urol; 2021 Sep; 206(3):548-557. PubMed ID: 33881933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
    Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
    Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.
    Koch A; Hatina J; Rieder H; Seifert HH; Huckenbeck W; Jankowiak F; Florl AR; Stoehr R; Schulz WA
    Cell Oncol (Dordr); 2012 Aug; 35(4):243-57. PubMed ID: 22669776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder.
    van Doeveren T; Nakauma-Gonzalez JA; Mason AS; van Leenders GJLH; Zuiverloon TCM; Zwarthoff EC; Meijssen IC; van der Made AC; van der Heijden AG; Hendricksen K; van Rhijn BWG; Voskuilen CS; van Riet J; Dinjens WNM; Dubbink HJ; van de Werken HJG; Boormans JL
    Int J Cancer; 2021 Feb; 148(4):981-987. PubMed ID: 33006377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
    Chang IW; Lin VC; Hung CH; Wang HP; Lin YY; Wu WJ; Huang CN; Li CC; Li WM; Wu JY; Li CF
    World J Urol; 2015 Nov; 33(11):1777-89. PubMed ID: 25813210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological significance of TUBB3 in upper tract urothelial carcinoma and possible application in urine cytology.
    Kobayashi G; Hayashi T; Sentani K; Uraoka N; Fukui T; Kido A; Katsuya N; Ishikawa A; Babasaki T; Sekino Y; Nose H; Hinata N; Oue N
    Pathol Int; 2023 Sep; 73(9):444-455. PubMed ID: 37589430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Ki-67 and E-cadherin expression on lymphovascular invasion in upper urinary tract urothelial carcinoma.
    Stojnev S; Krstić M; Velicković LJ; Petrović AR; Milojković M; Jovanović I; Stokanović D; Ugrenović S
    Vojnosanit Pregl; 2015 Nov; 72(11):982-8. PubMed ID: 26731972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma.
    Katayama S; Mori K; Schuettfort VM; Pradere B; Mostafaei H; Quhal F; Rajwa P; Motlagh RS; Laukhtina E; Moschini M; Grossmann NC; Araki M; Teoh JY; Rouprêt M; Margulis V; Enikeev D; Karakiewicz PI; Abufaraj M; Compérat E; Nasu Y; Shariat SF
    Eur Urol Focus; 2022 May; 8(3):761-768. PubMed ID: 34053904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma.
    Grahn A; Eisfeldt J; Malm C; Foroughi Asl H; Jaremko G; Tham E; Brehmer M
    BJU Int; 2022 Jul; 130(1):92-101. PubMed ID: 34375486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
    Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
    Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma.
    Eich ML; Tregnago AC; Faraj SF; Palsgrove DN; Fujita K; Bezerra SM; Munari E; Sharma R; Chaux A; Netto GJ
    Virchows Arch; 2019 Jan; 474(1):21-27. PubMed ID: 30338346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.